Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:

Gliatech

This article was originally published in The Gray Sheet

  • News

Executive Summary

Health Policy Associates hired as independent auditor to assist firm in responding to FDA's Application Integrity Policy (AIP) letter questioning post-market data for the Adcon-L gel anti-adhesion product for lumbar surgery. FDA recently suspended review of one premarket approval application and two PMA supplements submitted by the firm (1"The Gray Sheet" Jan. 1, 2001, p. 5)

You may also be interested in...



Adcon Data Will Be Evaluated By Third Party In Wake Of FDA Action - Gliatech

Gliatech will contract an independent evaluator to review magnetic resonance imaging data associated with postmarket studies of the company's Adcon-L gel anti-adhesion product for lumbar surgery.

Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

Table

View full table

Tags:
UsernamePublicRestriction

Register

MT014494

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By